Claims:

1. A compound of formula (I) or a pharmaceutically or veterinarily acceptable salt, hydrate or solvate thereof:

5 wherein

20

25

 R_1 and R_3 independently represent H; F; CI; Br; -NO₂; -CN; C₁-C₆ alkyl optionally substituted by F or CI; or C₁-C₆ alkoxy optionally substituted by F;

10 R₄ represents a carboxylic acid group (-COOH) or an ester thereof, or $-C(=O)NR_6R_7$, $-NR_7C(=O)R_6$, $-NR_7C(=O)OR_6$, $-NHC(=O)NR_7R_6$ or $-NHC(=S)NR_7R_6$ wherein

 R_6 represents H, or a radical of formula $-(Alk)_m$ -Q wherein

15 m is 0 or 1

Alk is an optionally substituted divalent straight or branched C_{1-} C_{12} alkylene, or C_2 - C_{12} alkenylene, or C_2 - C_{12} alkynylene radical or a divalent C_3 - C_{12} carbocyclic radical, any of which radicals may contain one or more -O-, -S- or $-N(R_8)$ - links wherein R_8 represents H or C_1 - C_4 alkyl, C_3 - C_4 alkenyl, C_3 - C_4 alkynyl, or C_3 - C_6 cycloalkyl, and

Q represents H; -NR $_9$ R $_{10}$ wherein R $_9$ and R $_{10}$ independently represents H; C $_1$ -C $_4$ alkyl; C $_3$ -C $_4$ alkenyl; C $_3$ -C $_4$ alkynyl; C $_3$ -C $_6$ cycloalkyl; an ester group; an optionally substituted carbocyclic or heterocyclic group; or R $_9$ and R $_{10}$ form a ring when taken

15

20

together with the nitrogen to which they are attached, which ring is optionally substituted; and

R₇ represents H or C₁-C₆ alkyl; or when taken together with the atom or atoms to which they are attached R₆ and R₇ form an optionally substituted monocyclic heterocyclic ring having 5, 6 or 7 ring atoms; and

X represents a bond or a divalent radical of formula $-(Z)_n$ -(Alk)- or -(Alk)- $(Z)_n$ - wherein Z represents -O-, -S- or -NH-, Alk is as defined in relation to R₆ and n is 0 or 1.

- 2. A compound as claimed in claim 1 wherein the radical R_4X is in the 4-position of the phenyl ring.
- 3. A compound as claimed in claim 1 or claim 2 wherein X is a bond.
- 4. A compound as claimed in any of the preceding claims wherein R_3 is hydrogen.
- 5. A compound as claimed in any of the preceding claims wherein R_1 is hydrogen or fluoro.
- 6. A compound as claimed in any of the preceding claims wherein R_4 represents $-C(=O)NR_6R_7$ wherein R_6 and R_7 are as defined in claim 1.
 - 7. A compound as claimed in any of the preceding claims wherein R_4 represents $-NHC(=O)NR_7R_6$ wherein R_6 and R_7 are as defined in claim 1.
- 30 8. A compound as claimed in claim 7 wherein R₆ is a quinuclidinyl radical.
 - 9. A compound as claimed in any of the preceding claims wherein R_6 represents a radical of formula $-(Alk)_m$ -Q wherein m is 1 and the divalent radical Alk contains 3 or 4 carbon atoms and is unsubstituted, and Q

represents -NR $_9$ R $_{10}$ wherein R $_9$ and R $_{10}$ independently represent H; C $_1$ -C $_4$ alkyl; C $_3$ -C $_4$ alkenyl; C $_3$ -C $_4$ alkynyl; C $_3$ -C $_6$ cycloalkyl; an ester group; an optionally substituted carbocyclic or heterocyclic group; or form a ring when taken together with the nitrogen to which they are attached, which ring is optionally substituted.

5

- 10. A compound as claimed in any of claims 6 to 8 wherein R_7 is hydrogen.
- 11. A compound as claimed in claim 1 wherein Q represents H; -CF₃; -OH;
 -SH; -NR₈R₈ wherein each R₈ independently represents H; C₁-C₄ alkyl; C₃-C₄ alkenyl; C₃-C₄ alkynyl; C₃-C₆ cycloalkyl; an ester group; an optionally substituted aryl, aryloxy, cycloalkyl, cycloalkenyl or heterocyclic group; or form a ring when taken together with the nitrogen to which they are attached; and
- R_7 represents H or C_1 - C_6 alkyl; or when taken together with the atom or atoms to which they are attached R_6 and R_7 form a monocyclic heterocyclic ring having 5, 6 or 7 ring atoms.
- 12. A compound as claimed in claim 11 wherein R₄ represents a carboxylic
 20 acid group (-COOH) or an ester group of formula –COOR wherein R is methyl, ethyl, n- or iso-propyl, n-, sec- or tert-butyl or benzyl.
- 13. A compound as claimed in claim 11 or claim 12 wherein R₆ represents a radical of formula –(Alk)_m-Q wherein m is 1, Alk is –CH₂-, -CH₂CH₂-,
 25 -CH₂CH₂-, or -CH₂CH(CH₃)CH₂-, or a divalent cyclopropylene, cyclopentylene or cyclohexylene radical, optionally substituted by OH, oxo, CF₃, methoxy or ethoxy, and Q represents hydrogen; -NR₈R₈ wherein each R₈ may be the same or different and selected from hydrogen, methyl, ethyl, n- or isopropyl or tert-butyl; a methyl, ethyl or benzyl ester; or an optionally
 30 substituted phenyl, phenoxy, cyclopentyl, cyclohexyl, furyl, thienyl, piperidyl, or piperazinyl group.
 - 14. A compound as claimed in any of claims 11 to 13 wherein R_7 represents methyl, ethyl, n- or iso-propyl, n-, sec- or tert-butyl; or when taken

WO 2004/081011 PCT/GB2004/001008

together with the atom or atoms to which they are attached R_6 and R_7 form a monocyclic heterocyclic ring having 5, 6 or 7 ring atoms;

- 15. A compound as claimed in any of claims 11 to 14 wherein R_1 is H, F, Cl, methyl, methoxy, or methylenedioxy.
 - 16 A compound as claimed in any of claims 11 to 14 wherein R_1 is F, in the 6-position of the 3-oxo-1,3-dihydro-2H-pyrazolo[4,3-c]cinnolin-2-yl ring system.

10

5

- 17. A compound as claimed in any of claims 11 to 16 wherein R_3 is H, F, CI, methyl, methoxy, or methylenedioxy.
- 18. A compound as claimed in any of claims 11 to 17 wherein X is a bond, or a $-CH_2$ or $-CH_2CH_2$ radical.
 - 19. A compound of formula (IC) or a pharmaceutically or veterinarily acceptable salt, hydrate or solvate thereof:

- wherein X and R₄ are as specified in any of claims 3, 7 to 10 or 11 to 18.
 - 20. A compound as claimed in claim 18 wherein the radical R_4X is in the 4-position of the phenyl ring.
- 25 21. A compound as claimed in claim 19 or claim 20 wherein X is a bond and R_4 is $-C(=O)NR_6R_7$ wherein R_6 and R_7 are as specified in claim 11, or claim 13 or 14 respectively.

22. The compound 4-(6-fluoro-3-oxo-1,3-dihydro-pyrazolo[4,3-c]cinnolin-2-yl)-N-(2,2-difluoro-ethylyl)-benzamide, of formula (A)

- or a pharmaceutically or veterinarily acceptable salt, hydrate or solvate thereof.
 - 23. The compound N-[3-(tert-butyl-methyl-amino)-butyl]-4-(6-fluoro-3-oxo-1,3-dihydro-pyrazolo[4,3-c]cinnolin-2-yl)-benzamide, of formula (B):

10

or a pharmaceutically or veterinarily acceptable salt, hydrate or solvate thereof.

24. A pharmaceutical or veterinary composition comprising a compound as
 15 claimed in any of claims 1 to 23 together with a pharmaceutically or veterinarily acceptable excipient or carrier.

25. A compound as claimed in any of claims 1 to 23 for use in the treatment of conditions which benefit from immunomodulation.

72

PCT/GB2004/001008

WO 2004/081011

15

20

- 26. The use of a compound as claimed in any of claims 1 to 23 in the
 5 manufacture of a medicament for the treatment of conditions which benefit from immunomodulation,
- 27. A method of immunomodulation in mammals, including humans, comprising administration to a mammal in need of such treatment an
 immunomodulatory effective dose of a compound as claimed in any of claims
 1 to 23.
 - 28, A compound for use as claimed in claim 25, the use as claimed in claim 26 or a method as claimed in claim 27 wherein the immunomodulation is immuno-inhibition.
 - 29. A compound for use as claimed in claim 25, the use as claimed in claim 26 or a method as claimed in claim 27 wherein the condition is autoimmune disease, rheumatoid arthritis, multiple sclerosis, diabetes, asthma, transplantation, systemic lupus erythematosis and psoriasis.